www.fdanews.com/articles/204710-annoviant-gets-grant-to-develop-cardiac-device
Annoviant Gets Grant to Develop Cardiac Device
October 6, 2021
Atlanta, Ga.-based Annoviant has been awarded a two-year, $1.85 million grant to help it develop and prepare to market its TxGuard pulmonary-valved conduit.
The device, which is for treatment of congenital heart disease — mainly in pediatric patients — uses materials designed to allow regeneration with host cells, enabling the device to grow with children.
In the U.S., an estimated 2,500 newborns are born each year with a heart defect that requires the use of a substitute conduit artery.
The grant from the National Institutes of Health is an extension of a technology transfer grant the company received in 2019.